Comparative Pharmacology
Head-to-head clinical analysis: BENICAR HCT versus TELMISARTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR HCT versus TELMISARTAN.
BENICAR HCT vs TELMISARTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Angiotensin II receptor antagonist; selectively blocks the binding of angiotensin II to AT1 receptors, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
40 mg orally once daily; range 20-80 mg/day
None Documented
None Documented
Clinical Note
moderateTelmisartan + Benzydamine
"The risk or severity of adverse effects can be increased when Telmisartan is combined with Benzydamine."
Clinical Note
moderateTelmisartan + Droxicam
"The risk or severity of adverse effects can be increased when Telmisartan is combined with Droxicam."
Clinical Note
moderateTelmisartan + Loxoprofen
"The risk or severity of adverse effects can be increased when Telmisartan is combined with Loxoprofen."
Clinical Note
moderateTelmisartan + Clonixin
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
Terminal half-life is approximately 24 hours (range 20–30 hours), supporting once-daily dosing without significant accumulation.
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Primarily biliary-fecal (approximately 97% unchanged in feces); renal excretion accounts for <1% of the dose.
Category C
Category D/X
ARB + Thiazide Diuretic
ARB
"The risk or severity of adverse effects can be increased when Telmisartan is combined with Clonixin."